Kamada Ltd. (KMDA) Earns Buy Rating from Jefferies Group
Other research analysts also recently issued research reports about the stock. HC Wainwright reiterated a buy rating and set a $10.00 price target on shares of Kamada in a research report on Saturday, September 3rd. Zacks Investment Research upgraded shares of Kamada from a hold rating to a buy rating and set a $4.50 target price on the stock in a research report on Thursday, August 4th. Finally, TheStreet upgraded shares of Kamada from a sell rating to a hold rating in a research report on Monday, September 26th.
Shares of Kamada (NASDAQ:KMDA) opened at 5.40 on Friday. Kamada has a 12-month low of $3.26 and a 12-month high of $6.29. The company’s 50 day moving average is $5.50 and its 200 day moving average is $4.45. The firm’s market capitalization is $196.66 million.
A hedge fund recently bought a new stake in Kamada stock. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Kamada Ltd. (NASDAQ:KMDA) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 463,434 shares of the company’s stock, valued at approximately $1,701,000. Migdal Insurance & Financial Holdings Ltd. owned about 1.21% of Kamada as of its most recent SEC filing. Hedge funds and other institutional investors own 5.31% of the company’s stock.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
Receive News & Stock Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related stocks with our FREE daily email newsletter.